#Israel #NESS ZIONA #Mileutis #Dr. Joachim Hasenmaier #Mr. Aaron Schacht

Mileutis Enters New Phase with Strong Board Appointments

Mileutis, a groundbreaking biopharmaceutical company from Israel, is poised for significant advancement with the recent appointment of Dr. Joachim Hasenmaier and Mr. Aaron Schacht to its Board of Directors. This strategic move aims to further embed sustainability into animal health practices, particularly within the dairy industry, as Mileutis steps into its next growth chapter.

Expanding Leadership for a Sustainable Future

The core focus of Mileutis is to innovate and provide solutions for the dairy sector, emphasizing antibiotic-free alternatives. With over three decades of experience, Dr. Joachim Hasenmaier has held pivotal roles in both human and animal health sectors. He is notably recognized for his tenure as Board Member and Head of Animal Health at Boehringer Ingelheim, where he played a vital role in propelling the division toward global leadership through innovative strategies and acquisitions. His academic credentials are formidable, boasting degrees in veterinary medicine and virology/immunology from top institutions including the Kellogg School of Management. Dr. Hasenmaier stated, “I’ve seen firsthand the urgent need for sustainable, science-backed alternatives to antibiotics in animal health. Mileutis is on a clear path to delivering that.”

Complementing his expertise is Aaron Schacht, current CEO of BiomEdit, Inc., a biotech company supported by the Gates Foundation. With a robust history in the industry, Schacht previously spearheaded R&D and Business Development at Elanco Animal Health, where he was influential in numerous acquisitions and product introductions, greatly impacting the company’s trajectory post-IPO. His excitement about joining Mileutis is palpable, as he noted, “Mileutis is tackling one of the most pressing challenges in the dairy industry.”

Pioneering Innovative Solutions

The upcoming initiatives from Mileutis include the development of peptide-based therapies, specifically IMILAC™ and MILAC™, products that are not only effective but also align with the company's commitment to sustainability and animal welfare. These offerings propose a residue-free alternative for common dairy industry challenges, including mastitis, which significantly impacts milk quality and animal health. As outlined by David Javier Iscovich, CEO and Chairman of Mileutis, “The addition of Dr. Hasenmaier and Mr. Schacht to our Board marks a significant milestone for Mileutis.”

Commitment to Transforming Dairy

As the dairy industry faces growing scrutiny over antibiotic use, Mileutis is uniquely positioned to lead the charge towards responsible, sustainable practices. With its peptide-based therapies, the company is committed to elevating animal welfare while ensuring the quality of milk produced. The insights and leadership of Dr. Hasenmaier and Mr. Schacht further bolster Mileutis’s mission to revolutionize the industry.

In conclusion, Mileutis is not just aiming to innovate; it is striving to set a new standard in the dairy sector. With the expertise of newly appointed board members, the company is prepared to tackle the global challenges posed by antimicrobial resistance (AMR) and steer the dairy industry toward a healthier, more sustainable future. For ongoing updates and information about their developments, visit their website at Mileutis.